23 results
8-K
EX-99.1
COCP
Cocrystal Pharma Inc
28 Mar 24
Cocrystal Pharma Reports 2023 Financial Results and Provides Updates on its Antiviral Drug-Development Programs
8:00am
the Company’s submission of a Pre-IND briefing package improves clarity on regulatory requirements for Phase 2b influenza A clinical trial with oral … and business activities.
“We are highly encouraged by the FDA’s feedback to our Pre-Investigational New Drug (Pre-IND) package, which provides greater
8-K
EX-99.1
COCP
Cocrystal Pharma Inc
19 Mar 24
Cocrystal Pharma Receives Pre-IND Responses from the FDA on Oral CC-42344 for Treating Influenza A
8:30am
filing the trial design. The feedback was provided in a written response to a Pre-IND package and questions submitted by the Company in January 2024
8-K
EX-99.1
COCP
Cocrystal Pharma Inc
23 Mar 22
Cocrystal Pharma Reports 2021 Financial Results and Provides Updates on Development Programs and Milestones
4:05pm
the U.S. Food and Drug Administration (FDA) on our pre-IND briefing package for CDI-45205 that provide valuable information in designing Phase 1
8-K
EX-99.1
8kem vpbncw51y4xqyov
15 Nov 21
Cocrystal Pharma Reports Third Quarter Financial Results and Provides an Update on Development
8:00am
8-K
EX-1.1
devg1kkxs
31 Oct 19
Entry into a Material Definitive Agreement
9:29am
8-K
EX-1.1
urtu8n9e
30 Oct 19
Entry into a Material Definitive Agreement
4:38pm
8-K
EX-1.1
j1wn070wvdcz bxt
20 Jul 18
Entry into a Material Definitive Agreement
4:50pm
8-K
EX-1.1
0l0vmze
2 May 18
Entry into a Material Definitive Agreement
4:13pm
8-K
EX-10.1
oeka6awiq7frkevyxqa
18 Apr 13
Unregistered Sales of Equity Securities
12:00am
424B7
m4bdw
26 Feb 13
Prospectus with selling stockholder info
12:00am